183 related articles for article (PubMed ID: 25762052)
1. Comparison of local reactions to oxaliplatin infusions by peripheral versus central venous administration.
To YY; Sutcliffe KJ; Hoen HM; Swaney RA; Nicholls JD; Crocenzi TS
J Oncol Pharm Pract; 2016 Apr; 22(2):256-60. PubMed ID: 25762052
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.
Shao YY; Hu FC; Liang JT; Chiu WT; Cheng AL; Yang CH
J Formos Med Assoc; 2010 May; 109(5):362-8. PubMed ID: 20497869
[TBL] [Abstract][Full Text] [Related]
3. A midline for oxaliplatin infusion: the myth of safety devices.
Masters B; Hickish T; Cidon EU
BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24903726
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
Wong JT; Ling M; Patil S; Banerji A; Long A
J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
6. The Effects of Prolonged Infusion on Reducing Oxaliplatin Hypersensitivity Reactions.
Zhang X; Zhao Y; Zheng Y; Dong Y
J Investig Allergol Clin Immunol; 2017; 27(1):65-66. PubMed ID: 28211349
[No Abstract] [Full Text] [Related]
7. Hypersensitivity reactions to oxaliplatin in two asian patients.
Ng CV
Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
Thomas RR; Quinn MG; Schuler B; Grem JL
Cancer; 2003 May; 97(9):2301-7. PubMed ID: 12712487
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin.
Yamauchi H; Goto T; Takayoshi K; Sagara K; Uoi M; Kawanabe C; Matsunaga M; Miyoshi T; Uchino K; Misumi N; Nishino T
Eur J Cancer Care (Engl); 2015; 24(1):111-6. PubMed ID: 24304429
[TBL] [Abstract][Full Text] [Related]
11. [Investigating the incidence of injection-site reactions associated with administration of oxaliplatin into a peripheral vein and management local adverse reactions].
Hibi S; Tatematsu M; Nishio S; Miyatani M; Tosaki K; Ohara M; Maeda T; Tomita N; Kawai M; Ina K; Oishi K; Muro K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1447-52. PubMed ID: 21918339
[TBL] [Abstract][Full Text] [Related]
12. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y
Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
Park SJ; Lee KY; Park WS; Min SY
Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
Gammon D; Bhargava P; McCormick MJ
Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
Kim BH; Bradley T; Tai J; Budman DR
Oncology; 2009; 76(4):231-8. PubMed ID: 19246947
[TBL] [Abstract][Full Text] [Related]
16. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution.
Lenz G; Hacker UT; Kern W; Schalhorn A; Hiddemann W
Anticancer Drugs; 2003 Oct; 14(9):731-3. PubMed ID: 14551506
[TBL] [Abstract][Full Text] [Related]
17. Hypersensitivity reactions to oxaliplatin: what nurses need to know.
Bonosky K; Miller R
Clin J Oncol Nurs; 2005 Jun; 9(3):325-30. PubMed ID: 15973843
[TBL] [Abstract][Full Text] [Related]
18. [Etiology and management of venous pain during intravenous administration of oxaliplatin].
Matsuyama K; Mishima H; Ueno H; Kajihara K; Morioka A; Morimoto S; Yamauchi K; Honda Y; Komori K; Tsujinaka T
Gan To Kagaku Ryoho; 2011 Mar; 38(3):411-4. PubMed ID: 21403443
[TBL] [Abstract][Full Text] [Related]
19. Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain.
Kawazoe H; Sumikawa S; Nakauchi K; Yakushijin Y; Yamamoto Y; Watanabe Y; Tanaka A; Araki H
Int J Clin Pharm; 2017 Dec; 39(6):1291-1297. PubMed ID: 29027645
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin infusion-related venous pain: prevention by simultaneous intravenous fluids.
van Ravensteijn S; van Merrienboer B; van Asten S; Pruijt J; Hilbink M; Tol J
BMJ Support Palliat Care; 2021 Jun; 11(2):226-229. PubMed ID: 32451327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
